For patients with advanced CKD, low risk of nephrogenic systemic fibrosis with group II GBCAs
Pediatric News ,
Background: With more than 500 cases of NSF reported during 1997-2007, a black box warning advises against use of all GBCAs in…
Background: With more than 500 cases of NSF reported during 1997-2007, a black box warning advises against use of all GBCAs in…
Use of a group II gadolinium-based contrast agent (GBCA) in patients with stage 4 or 5 chronic kidney disease is associated…
1. In a systematic review and meta-analysis of the use of group II (low risk) gadolinium-based contrast agents (GBCA) for MRI…
Patients with chronic kidney disease (CKD) who receive a gadolinium-based contrast agent (GBCA) have a low risk of developing…